Lyell lays off 25% of staff and CMO leaves as com­pa­ny fore­shad­ows first clin­i­cal da­ta next year

Lyell Im­munophar­ma is lay­ing off 25% of its work­force, and its chief med­ical of­fi­cer is leav­ing, ac­cord­ing to the Bay Area biotech com­pa­ny’s third-quar­ter re­port.

The com­pa­ny had 274 em­ploy­ees as of De­cem­ber of last year. It de­clined to spec­i­fy how many work­ers are part of the lay­offs.

“We have re­struc­tured our com­pa­ny to pri­or­i­tize in­vest­ment in our clin­i­cal-stage pro­grams and core re­search plat­forms and have stream­lined op­er­a­tions,” Lyell pres­i­dent and CEO Lynn Seely said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER